429 related articles for article (PubMed ID: 25612741)
1. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.
Kämpf MM; Braun M; Sirena D; Ihssen J; Thöny-Meyer L; Ren Q
Microb Cell Fact; 2015 Jan; 14():12. PubMed ID: 25612741
[TBL] [Abstract][Full Text] [Related]
2. Production of glycoprotein vaccines in Escherichia coli.
Ihssen J; Kowarik M; Dilettoso S; Tanner C; Wacker M; Thöny-Meyer L
Microb Cell Fact; 2010 Aug; 9():61. PubMed ID: 20701771
[TBL] [Abstract][Full Text] [Related]
3. Outer Membrane Vesicles Derived from
Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
[TBL] [Abstract][Full Text] [Related]
4. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
Phalipon A; Costachel C; Grandjean C; Thuizat A; Guerreiro C; Tanguy M; Nato F; Vulliez-Le Normand B; Bélot F; Wright K; Marcel-Peyre V; Sansonetti PJ; Mulard LA
J Immunol; 2006 Feb; 176(3):1686-94. PubMed ID: 16424198
[TBL] [Abstract][Full Text] [Related]
5. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
[TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
[TBL] [Abstract][Full Text] [Related]
7. Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering.
Ihssen J; Haas J; Kowarik M; Wiesli L; Wacker M; Schwede T; Thöny-Meyer L
Open Biol; 2015 Apr; 5(4):140227. PubMed ID: 25833378
[TBL] [Abstract][Full Text] [Related]
8. Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.
Ravenscroft N; Braun M; Schneider J; Dreyer AM; Wetter M; Haeuptle MA; Kemmler S; Steffen M; Sirena D; Herwig S; Carranza P; Jones C; Pollard AJ; Wacker M; Kowarik M
Glycobiology; 2019 Aug; 29(9):669-680. PubMed ID: 31206156
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
10. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
Jennison AV; Roberts F; Verma NK
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.
Ravenscroft N; Haeuptle MA; Kowarik M; Fernandez FS; Carranza P; Brunner A; Steffen M; Wetter M; Keller S; Ruch C; Wacker M
Glycobiology; 2016 Jan; 26(1):51-62. PubMed ID: 26353918
[TBL] [Abstract][Full Text] [Related]
12. The Shigella flexneri serotype Y vaccine candidate SFL124 originated from a serotype 2a background.
Roberts F; Jennison AV; Verma NK
FEMS Immunol Med Microbiol; 2005 Aug; 45(2):285-9. PubMed ID: 15963704
[TBL] [Abstract][Full Text] [Related]
13. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
[TBL] [Abstract][Full Text] [Related]
14. PglB function and glycosylation efficiency is temperature dependent when the pgl locus is integrated in the Escherichia coli chromosome.
Terra VS; Mauri M; Sannasiddappa TH; Smith AA; Stevens MP; Grant AJ; Wren BW; Cuccui J;
Microb Cell Fact; 2022 Jan; 21(1):6. PubMed ID: 34986868
[TBL] [Abstract][Full Text] [Related]
15. Glycoconjugation of Shigella flexneri type 2a O-polysaccharide with CRM
Narayana PVSLSS; Dutta JR
Biologicals; 2021 Jul; 72():1-9. PubMed ID: 34247915
[TBL] [Abstract][Full Text] [Related]
16. Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins.
Cuccui J; Wren B
J Pharm Pharmacol; 2015 Mar; 67(3):338-50. PubMed ID: 25244672
[TBL] [Abstract][Full Text] [Related]
17. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
Citiulo F; Necchi F; Mancini F; Rossi O; Aruta MG; Gasperini G; Alfini R; Rondini S; Micoli F; Rappuoli R; Saul A; Martin LB
PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009826. PubMed ID: 34644291
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
19. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005728. PubMed ID: 28727722
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
